Prot#GS-US-419-4016: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date5/30/18 → 5/31/22

Funding

  • Quintiles, Inc. (GS-US-419-4016 // GS-US-419-4016)
  • Gilead Sciences, Inc. (GS-US-419-4016 // GS-US-419-4016)